M-ZOLE 3 COMBINATION PACK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for M-ZOLE 3 COMBINATION PACK (M-ZOLE 3 COMBINATION PACK).
Miconazole inhibits fungal CYP450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity. Zinc pyrithione inhibits fungal growth by disrupting membrane transport and inhibiting energy metabolism.
| Metabolism | Miconazole is primarily metabolized by hepatic CYP3A4; zinc pyrithione is minimally absorbed and metabolized locally. |
| Excretion | Renal: ~70-80% as unchanged drug and metabolites; biliary/fecal: ~20% |
| Half-life | Terminal elimination half-life 20-30 hours in healthy adults; prolonged in renal impairment (up to 40-50 hours) and hepatic impairment |
| Protein binding | ~99% primarily to albumin |
| Volume of Distribution | 0.6-1.2 L/kg, indicating extensive tissue distribution |
| Bioavailability | Oral: ~90% |
| Onset of Action | Oral: 1-2 hours; IV: immediate |
| Duration of Action | Oral: 12-24 hours; IV: 24-48 hours, depending on dose |
A single oral dose of 3 tablets (M-ZOLE 3 COMBINATION PACK) as a one-time treatment.
| Dosage form | CREAM, SUPPOSITORY |
| Renal impairment | No adjustment required for mild-to-moderate renal impairment. Contraindicated in severe renal impairment (eGFR <30 mL/min). |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in moderate impairment (Child-Pugh class B) with dose reduction to half. |
| Pediatric use | Not recommended for children under 12 years. For children ≥12 years, same adult single dose of 3 tablets. |
| Geriatric use | No specific dose adjustment needed; monitor for adverse effects due to potential age-related renal or hepatic decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for M-ZOLE 3 COMBINATION PACK (M-ZOLE 3 COMBINATION PACK).
| Breastfeeding | Miconazole is minimally absorbed after vaginal or topical application; systemic levels are low. M/P ratio is not established. Excretion into breast milk is unlikely to be clinically significant. Compatible with breastfeeding, but avoid direct application to nipples. |
| Teratogenic Risk | M-ZOLE 3 COMBINATION PACK contains miconazole (azole antifungal). Teratogenic risk: First trimester – limited human data, animal studies show no consistent teratogenicity; however, high-dose systemic azoles have been associated with miscarriage and congenital anomalies in some studies. Second and third trimesters – generally considered low risk with topical/vaginal use, as systemic absorption is minimal. Overall, avoid in first trimester unless benefit outweighs risk; use with caution in second and third trimesters. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component of the product","Children under 2 years of age (unless directed by a doctor)"]
| Precautions | ["For external use only; avoid contact with eyes","Discontinue if irritation or allergic reaction occurs","Do not use on open wounds or damaged skin","Not for vaginal or oral use"] |
Loading safety data…
| Fetal Monitoring | For vaginal use: monitor for signs of local irritation, hypersensitivity, or superinfection. No specific fetal monitoring required due to minimal systemic absorption. |
| Fertility Effects | No adverse effects on fertility reported with topical/vaginal miconazole. Systemic azoles may affect hormone levels, but this is not relevant for the combination pack's route. |